Alpine Associates Management’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Alpine Associates Management’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,131,000	Closed	-$81.9M	–	49
2023 Q2	$81.9M	Buy	+2,131,000	New	+$54.7M	3.69%	11

Alpine Associates Management's KDNY Position: Q3 2023 in Review

Alpine Associates Management sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 2,131,000 shares — an estimated $81.9M sold.

Alpine Associates Management first reported a position in KDNY in Q2 2023 and held it in 1 quarter. The position peaked at $81.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Alpine Associates Management reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Alpine Associates Management sold 2,131,000 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $81.9M.
Alpine Associates Management first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
Alpine Associates Management's Chinook Therapeutics, Inc. Common Stock position peaked at $81.9M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Alpine Associates Management's 13F filing for Q3 2023, filed 8 Nov 2023.